Charu Rajput1, Mingyuan Han1, Tomoko Ishikawa1, Jing Lei1, Seyedehzarifeh Jazaeri1, J Kelley Bentley1, Marc B Hershenson2. 1. Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Mich. 2. Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Mich; Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Mich. Electronic address: mhershen@umich.edu.
Abstract
BACKGROUND: Early-life wheezing-associated respiratory tract infection by rhinovirus (RV) is a risk factor for asthma development. Infants are infected with many different RV strains per year. OBJECTIVE: We previously showed that RV infection of 6-day-old BALB/c mice induces a mucous metaplasia phenotype that is dependent on type 2 innate lymphoid cells (ILC2s). We hypothesized that early-life RV infection alters the response to subsequent heterologous infection, inducing an exaggerated asthma-like phenotype. METHODS: Wild-type BALB/c mice and Rorafl/flIl7rcre mice lacking ILC2s were treated as follows: (1) sham on day 6 of life plus sham on day 13 of life, (2) RV-A1B on day 6 plus sham on day 13, (3) sham on day 6 plus RV-A2 on day 13, and (4) RV-A1B on day 6 plus RV-A2 on day 13. RESULTS: Mice infected with RV-A1B at day 6 and sham at day 13 showed an increased number of bronchoalveolar lavage eosinophils and increased expression of IL-13 mRNA but not expression of IFN-γ mRNA (which is indicative of a type 2 immune response), whereas mice infected with sham on day 6 and RV-A2 on day 13 of life demonstrated increased IFN-γ expression (which is a mature antiviral response). In contrast, mice infected with RV-A1B on day 6 before RV-A2 infection on day 13 showed increased expression of IL-13, IL-5, Gob5, Muc5b, and Muc5ac mRNA; increased numbers of eosinophils and IL-13-producing ILC2s; and exaggerated mucus metaplasia and airway hyperresponsiveness. Compared with Rorafl/fl mice, Rorafl/flIl7rcre mice showed complete suppression of bronchoalveolar lavage eosinophils and mucous metaplasia. CONCLUSION: Early-life RV infection alters the response to subsequent heterologous infection, inducing an intensified asthma-like phenotype that is dependent on ILC2s.
BACKGROUND: Early-life wheezing-associated respiratory tract infection by rhinovirus (RV) is a risk factor for asthma development. Infants are infected with many different RV strains per year. OBJECTIVE: We previously showed that RV infection of 6-day-old BALB/c mice induces a mucous metaplasia phenotype that is dependent on type 2 innate lymphoid cells (ILC2s). We hypothesized that early-life RV infection alters the response to subsequent heterologous infection, inducing an exaggerated asthma-like phenotype. METHODS: Wild-type BALB/c mice and Rorafl/flIl7rcre mice lacking ILC2s were treated as follows: (1) sham on day 6 of life plus sham on day 13 of life, (2) RV-A1B on day 6 plus sham on day 13, (3) sham on day 6 plus RV-A2 on day 13, and (4) RV-A1B on day 6 plus RV-A2 on day 13. RESULTS:Miceinfected with RV-A1B at day 6 and sham at day 13 showed an increased number of bronchoalveolar lavage eosinophils and increased expression of IL-13 mRNA but not expression of IFN-γ mRNA (which is indicative of a type 2 immune response), whereas miceinfected with sham on day 6 and RV-A2 on day 13 of life demonstrated increased IFN-γ expression (which is a mature antiviral response). In contrast, miceinfected with RV-A1B on day 6 before RV-A2 infection on day 13 showed increased expression of IL-13, IL-5, Gob5, Muc5b, and Muc5ac mRNA; increased numbers of eosinophils and IL-13-producing ILC2s; and exaggerated mucus metaplasia and airway hyperresponsiveness. Compared with Rorafl/fl mice, Rorafl/flIl7rcre mice showed complete suppression of bronchoalveolar lavage eosinophils and mucous metaplasia. CONCLUSION: Early-life RV infection alters the response to subsequent heterologous infection, inducing an intensified asthma-like phenotype that is dependent on ILC2s.
Authors: Merci M H Kusel; Nicholas H de Klerk; Patrick G Holt; Tatiana Kebadze; Sebastian L Johnston; Peter D Sly Journal: Pediatr Infect Dis J Date: 2006-08 Impact factor: 2.129
Authors: Nele Sigurs; Per M Gustafsson; Ragnar Bjarnason; Fredrik Lundberg; Susanne Schmidt; Fridrik Sigurbergsson; Bengt Kjellman Journal: Am J Respir Crit Care Med Date: 2004-10-29 Impact factor: 21.405
Authors: Timotheus Y F Halim; Aric MacLaren; Mark T Romanish; Matthew J Gold; Kelly M McNagny; Fumio Takei Journal: Immunity Date: 2012-09-13 Impact factor: 31.745
Authors: Jun Young Hong; J Kelley Bentley; Yutein Chung; Jing Lei; Jessica M Steenrod; Qiang Chen; Uma S Sajjan; Marc B Hershenson Journal: J Allergy Clin Immunol Date: 2014-06-06 Impact factor: 10.793
Authors: Jun Young Hong; Yutein Chung; Jessica Steenrod; Qiang Chen; Jing Lei; Adam T Comstock; Adam M Goldsmith; J Kelley Bentley; Uma S Sajjan; Marc B Hershenson Journal: Respir Res Date: 2014-06-07
Authors: Timotheus Y F Halim; You Yi Hwang; Seth T Scanlon; Habib Zaghouani; Natalio Garbi; Padraic G Fallon; Andrew N J McKenzie Journal: Nat Immunol Date: 2015-11-02 Impact factor: 25.606
Authors: V S Pelly; Y Kannan; S M Coomes; L J Entwistle; D Rückerl; B Seddon; A S MacDonald; A McKenzie; M S Wilson Journal: Mucosal Immunol Date: 2016-02-17 Impact factor: 7.313
Authors: Evelien R van Meel; Herman T den Dekker; Niels J Elbert; Pauline W Jansen; Henriëtte A Moll; Irwin K Reiss; Johan C de Jongste; Vincent W V Jaddoe; Liesbeth Duijts Journal: Thorax Date: 2017-11-03 Impact factor: 9.139
Authors: Kim Tien Ng; Liang Jie Ng; Xiang Yong Oong; Jack Bee Chook; Kok Gan Chan; Yutaka Takebe; Adeeba Kamarulzaman; Kok Keng Tee Journal: Virol J Date: 2022-03-04 Impact factor: 4.099
Authors: Mingyuan Han; Haley A Breckenridge; Shiuhyang Kuo; Shilpi Singh; Adam G Goldsmith; Yiran Li; Jordan E Kreger; J Kelley Bentley; Marc B Hershenson Journal: Front Immunol Date: 2022-08-12 Impact factor: 8.786